| Inadequate iodine nutrition of pregnant women from Extremadura (Spain). | |
| | |
MedLine Citation:
|
PMID: 18644824 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the iodine nutrition of the pregnant women of the Spanish Autonomous Community Extremadura. There are approximately 10,000 births per year in Extremadura, which historically contains areas with endemic goiter (Las Hurdes). DESIGN: Population study in which a representative sample of pregnant women of the general population was analyzed, along with another sample of pregnant women from traditionally goitrogenic areas. With the collaboration of selected health centers, an additional sample of blood and urine was obtained within the primary health care pregnancy-monitoring program; these samples were sent to a single central laboratory. METHODS: Biochemistry: determination of iodine and creatinine in urine, and serum concentrations of thyroxine, free thyroxine, tri-iodothyronine, TSH, thyroglobulin, and two anti-thyroid antibodies. Each parameter was measured by means of a single specific RIA. RESULTS: Changes between the first trimester and later stages of pregnancy of all biochemical variables studied corresponded with those described for other European areas with a comparable iodine nutrition. Using the urinary iodine concentration value as an indicator of iodine ingestion, it was found that in the first trimester of pregnancy six out of ten women from Extremadura ingested less than the currently recommended amount (250 microg I/day), and approximately three out of ten of these women ingested less than half of this amount. CONCLUSIONS: It is imperative to implement in all Extremadura the generalized and controlled use of complements that contain 200-250 microg I/day throughout pregnancy and, if possible, before. |
| | |
Authors:
|
Javier Sánchez-Vega; Francisco Escobar del Rey; Humberto Fariñas-Seijas; Gabriella Morreale de Escobar |
Related Documents
:
|
15289044 - Prenatal toxicity of cyanide in goats--a model for teratological studies in ruminants. 6781794 - Hormone profile of t3, t4 at the end of pregnancy and during puerperium. 23639574 - Fetal growth factors and fetal nutrition. 23496304 - Can maternal serum placental growth factor estimation in early second trimester predict... 7627354 - Lack of evidence for a role of hla-dp in unexplained recurrent spontaneous abortion. 12962264 - Fetal and maternal plasma leptin levels during the second half of normal pregnancies an... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2008-07-21 |
Journal Detail:
|
Title: European journal of endocrinology / European Federation of Endocrine Societies Volume: 159 ISSN: 1479-683X ISO Abbreviation: Eur. J. Endocrinol. Publication Date: 2008 Oct |
Date Detail:
|
Created Date: 2008-09-22 Completed Date: 2008-10-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9423848 Medline TA: Eur J Endocrinol Country: England |
Other Details:
|
Languages: eng Pagination: 439-45 Citation Subset: IM |
Affiliation:
|
CICAB, Clinical Research Center, Extremadura University Hospital and Medical School, 07071 Badajoz, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Autoantibodies
/
blood Creatinine / blood, urine Female Goiter, Endemic / diagnosis, metabolism* Humans Iodine / administration & dosage, blood*, deficiency*, urine Nutrition Assessment* Pregnancy Pregnancy Complications / diagnosis, metabolism* Pregnancy Trimester, First Sodium Chloride, Dietary / administration & dosage Spain Thyrotropin / blood Thyroxine / blood Triiodothyronine / blood |
| Chemical | |
Reg. No./Substance:
|
0/Autoantibodies; 0/Sodium Chloride, Dietary; 0/iodized salt; 60-27-5/Creatinine; 6893-02-3/Triiodothyronine; 7488-70-2/Thyroxine; 7553-56-2/Iodine; 9002-71-5/Thyrotropin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Thyroid B-flow twinkling sign: a new feature of papillary cancer.
Next Document: Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after fai...